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Aims Right ventricular pacing for left ventricular outflow tract gradient reduction in hypertrophic obstructive cardiomy-




Thirty-four studies comprising 1135 patients met eligibility criteria. In the four blinded randomized controlled trials
(RCTs), pacing reduced gradient by 35% [95% confidence interval (CI) 23.2–46.9, P< 0.0001], but there was only a
trend towards improved New York Heart Association (NYHA) class [odds ratio (OR) 1.82, CI 0.96–3.44;
P= 0.066]. The unblinded observational studies reported a 54.3% (CI 44.1–64.6, P< 0.0001) reduction in gradient,
which was a 18.6% greater reduction than the RCTs (P= 0.0351 for difference between study designs).
Observational studies reported an effect on unblinded NYHA class at an OR of 8.39 (CI 4.39–16.04, P< 0.0001),
450% larger than the OR in RCTs (P= 0.0042 for difference between study designs). Across all studies, the gradient
progressively decreased at longer follow durations, by 5.2% per month (CI 2.5–7.9, P= 0.0001).
...................................................................................................................................................................................................
Conclusion Right ventricular pacing reduces gradient in blinded RCTs. There is a non-significant trend to reduction in NYHA
class. The bias in assessment of NYHA class in observational studies appears to be more than twice as large as any
genuine treatment effect.
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Introduction
Hypertrophic cardiomyopathy (HCM) is the most common cause of
sudden death in young adults with a prevalence of 0.2%.1 When asym-
metrical septal hypertrophy leads to left ventricular outflow tract ob-
struction (LVOTO) with associated systolic anterior motion of the
anterior mitral valve leaflet, this confers a diagnosis of the sub-
phenotype hypertrophic obstructive cardiomyopathy (HOCM, also
known as ‘obstructed HCM’), which occurs in around 70% of HCM
sufferers.1 Alongside contributing to mortality through multiple mech-
anisms, including heart failure and malignant arrhythmia, LVOTO pro-
duces significant morbidity, inducing symptoms of chest pain,
breathlessness, exertion intolerance, light-headedness, and syncope.
Management of symptomatic LVOTO is initially pharmacological
but interventions are available in the form of surgical septal
myectomy or percutaneous alcohol septal ablation, both carrying
risks of complication. Failure, intolerance and reluctance with
pharmacological and interventional treatment of LVOTO led to
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.interest in the use of right ventricular pacing as an alternative method
for gradient reduction and resultant symptomatic improvement.2,3
A number of studies, both randomized and observational, have
investigated the effect of dual chamber pacing in HOCM. We system-
atically analysed these to quantify the effect on LVOTO, left ventricu-
lar systolic function, symptoms and functional status.
Methods
We carried out a meta-analysis of studies that evaluated right ventricular
pacing in HOCM in accordance with PRISMA guidelines.4 We prospect-
ively registered this meta-analysis on the PROSPERO international regis-
ter of systematic reviews (registration number CRD42017062165).5
Search strategy
We searched PubMed and the Cochrane Central Register of Controlled
Trials for any studies [randomized controlled trials (RCTs), non-RCTs,
and uncontrolled observational studies] published in the English language
where adults with HOCM underwent atrial-synchronous right ventricular
pacing. Studies were included if prospectively determined clinically rele-
vant outcomes were reported: left ventricular outflow tract gradient
(LVOTg), New York Heart Association (NYHA) functional status, left
ventricular ejection fraction, exercise duration, and peak oxygen uptake
during cardiopulmonary exercise testing. Systematic reviews were exam-
ined for references to relevant studies. Any discrepancies were resolved
by consensus. The full search strategy is reported in the Supplementary
material online.
The study protocol was drafted by A.D.A. and revised by all co-
authors. Preliminary search and eligibility analysis was performed by K.C.
and Y.A. F.d.V. and A.D.A. performed an independent preliminary search.
Inclusion and exclusion criteria
We considered all studies of right ventricular pacing in HOCM. Studies
were eligible if they recruited patients with an elevated gradient
(>30 mmHg).1 We excluded case reports, studies of biventricular pacing,
or studies where pacing occurred was delivered in combination with
other invasive gradient reduction interventions such as septal ablation or
myomectomy.
Endpoints
The primary efficacy endpoint was change in gradient (DLVOTg). The
secondary efficacy outcomes were change in symptomatic and functional
status measured by NYHA class, exercise time, or peak oxygen uptake,
from baseline to follow-up. Detailed inclusion criteria for endpoints are
found in the Supplementary material online.
Follow-up
It was anticipated that the search would reveal trials of varying follow-up
duration. We prospectively determined that DLVOTg would be analysed
according to the following groups of mean follow-up durations: immedi-
ate (<12 h), short-term (12 h to 6 months), medium-term (>6 months to
<2 years), and long-term (>2 years). This would allow testing for progres-
sive change in LVOTg due to remodelling over time.6 Randomized studies
were pre-specified to be analysed separately from observational studies
with comparison between RCTs and non-randomized studies of similar
follow-up duration.
Data extraction and analysis
A.D.A., K.C., W.J.K., and F.d.V. performed data extraction. J.P.H. per-
formed meta-analysis and designed and carried out statistical method-
ology with contributions from H.Y.J., L.C., D.P.F., Z.I.W., and M.J.S.S. The
statistical programming environment R with the metafor package was
used for all statistical analysis. Random-effects meta-analyses were per-
formed using the restricted maximum likelihood estimator. For ordinal
categorical outcomes (NYHA), Agresti’s generalized odds ratios (ORs)
were first calculated for each trial before meta-analysis.7,8 Interactions be-
tween groups were assessed using a mixed effects meta-analytical model
with the variable in question as a moderator. We used the I2 statistic to
assess heterogeneity. Included RCTs were assessed using the Cochrane
risk of bias tool.
Results
We identified 604 study reports (flowchart in Figure 1), of which 34
were eligible for inclusion for at least one pre-specified outcome of
interest, comprising 1135 patients.6,9–40 There were four
RCTs,20,24,28,31 all blinded crossover trials, and 30 observational
Figure 1 Flow chart for study selection.














..studies.6,9–19,21–23,25–27,29,30,32–41 Baseline characteristics are in
Table 1 and design features are in Table 2. Most studies reported data
at multiple follow-up durations.6,10,11,13–17,20,23,24,27,31,34–38,40–42
Mean age was 55.5 years and mean baseline unpaced LVOTg was
78.9 mmHg.
Risk of bias
Trial quality for the four RCTs, assessed by the Cochrane risk of bias
assessment tool, is shown in Table 3. Three were rated as low risk of
bias due to double blinding but the fourth was single blinded. Lack of
randomization and lack of blinding put all 31 observational studies at
risk of bias.
Left ventricular outflow tract obstruction
Thirty-two studies reported mean change in LVOTg (DLVOTg) from
baseline for at least one follow-up duration. The results are shown in
Figure 2 for observational studies, Figure 3 for RCTs, and summarized
in Table 4.
....................................................................................................................................................................................................................
Table 1 Characteristics of included studies—baseline values






Javidgonbadi et al.a 2017 88 55 ± 18 48 2.3 ± 0.6 69 (16) 64 (66)
Jurado Roma´n et al. 2016 82 66 (range 22–88) 38 NA 73 ± 11 95 ± 37
Krejci et al. 2013 24 50 ± 17 NA 2.7 ± 0.5 70 ± 9 82 ± 46
Lucon et al. 2013 51 59 ± 14 47 2.7 ± 0.6 64 ± 8 79 ± 36
Yue-Cheng et al. 2013 37 52 ± 21 54 2.6 ± 0.8 64 ± 12 62 ± 11
Knyshov et al. 2013 49 38 ± 21 47 1.9 ± 0.8 NA 84 ± 15
Galve et al. 2010 50 62 ± 11 52 3.1 ± 0.3 76 ± 10 86 ± 29
Minami et al. 2010 24 52 ± 16 50 NA NA 89 ± 38
Sandı`n et al. 2009 72 64 ± 14 38 2.6 ± 0.5 67 ± 10 87 (IQR 61.5–115.2)
Binder et al. 2008 66 67 41 2.7 ± 0.7 NA 66 ± 36
Topilski et al. 2006 25 71 ± 12 48 3.2 ± 0.8 NA 92 ± 28
Hozumi et al. 2006 14 55 ± 16 79 NA 66 ± 6b 24 ± 12b
Megevand et al.b 2005 18 47 NA 2.4 NA 82 ± 35
Dimitrow et al. 2004 19 47 ± 16 52 3.2 ± 0.9 NA 77 ± 25
Mickelsen et al. 2004 11 69 ± 10 82 NA NA 96 ± 21
Betocchi et al. 2002 21 45 ± 15 52 3.1 ± 0.4 NA 77 ± 37
Achterberg et al. 2002 7 52 ± 13 43 3.1 ± 0.5 NA 88 ± 13
Sant’Anna et al. 1999 9 47 ± 15 33 2.3 ± 0.5 NA 92 ± 22
Park et al. 1999 10 62 ± 13 50 3.5 ± 0.5 NA 83 ± 44
Sakai et al. 1999 12 55 ± 8 58 2.3 ± 0.5 NA 106 ± 47
Maron et al. 1999 44 53 ± 17 46 NA NA 82 ± 33
Pak et al. 1998 5 48 ± 10 60 3 81 ± 8 67 ± 33
Simantirakis et al. 1998 8 56 ± 7 63 NA NA 70 ± 18
Nishimura et al. 1997 19 59 ± 13 53 2.9 ± 0.4 NA 76 ± 61c
Gadler et al. 1997 22 68 ± 14 27 3 ± 0.6 NA 86 ± 40
Kappenberger et al. 1997 83 53 (range 32–87) 60 2.6 ± 0.5 NA 70 ± 24
Slade et al. 1996 52 48 ± 18 61 2.7 ± 0.6 NA 78 ± 31
Nishimura et al.d 1996 21 58 ± 16 50 NA NA 73 ± 45
Gadler et al. 1996 22 65 ± 12 47 2.9 ± 0.6 NA 96 ± 33
Fananapazir et al. 1994 84 49 ± 16 50 3.2 ± 0.5 NA 96 ± 41
McAreavey et al. 1992 18 48 ± 14 44 3.3 ± 0.5 NA 94 ± 47
Jeanrenaud et al. 1992 13 56 ± 14 69 NA NA 82 ± 41
Fananapazir et al. 1992 44 49 ± 14 50 3.4 ± 0.5 NA 64 ± 7
McDonald et al. 1988 11 51 ± 15 55 3 ± 0.6 NA 43 ± 25
Values for age, NYHA, EF, and LVOTg are mean ± standard deviation unless otherwise stated. Values for male are percentages. NA if not reported.
NYHA, New York Heart Association class; LVEF, left ventricular ejection fraction; LVOTg, left ventricular outflow tract gradient.
aLVOTg and LVEF data for this trial are reported as median (interquartile range).
bBaseline LVEF and LVOTg in this study is immediately after pacing is switched off after period of pacing (rather than prior to pacing initiation as performed in the other
studies).
cValue reported from echocardiogram; 87 ± 54 on cardiac catheterization.
dThis study contains the data from the acute haemodynamic protocol of Nishimura et al.31

















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































..In the four RCTs (follow-up ranged from 1 months to 3 months),
pacing reduced LVOTg by 35%. The observational studies reported
slightly larger LVOTg reductions (Table 4).
Meta-regression showed progressively greater gradient reductions
at longer follow-up durations, by an average of 5.2% per month [con-
fidence interval (CI) 2.5–7.9, P= 0.0001].
We, therefore, compared gradient effect size of RCTs with obser-
vational studies at similar follow-up times (denoted short-term). The
observational studies reported a gradient reduction, which was
18.6% greater than RCTs (CI 1.3–36, P= 0.0351).
New York Heart Association status
As pre-specified, because there were too few studies reporting
NYHA, we did not sub-divide them by follow-up duration. The
results are displayed in Figures 4 and 5 and summarized in Table 4.
In RCTs, there was a trend towards improved NYHA class with
pacing (OR 1.82, CI 0.96–3.44; P= 0.066) but with considerable het-
erogeneity (I2 = 81.7%) as a result of one trial showing a particularly
prominent favourable effect.
In contrast, almost all of the observational studies (8/9) reported
marked improvement in NYHA class giving a combined OR of 8.39
(CI 4.39–16.04, P< 0.0001). This OR is over 450% of the OR for
RCTs: ratio of ORs 4.54 (CI 1.61–12.82, P= 0.0042).
Exercise and systolic function
For each of the other variables (ejection fraction, exercise duration,
and peak oxygen uptake) fewer than five studies reported the data
require, and therefore, meta-analysis was not conducted. Reported
changes in ejection fraction ranged from þ3% to -11%, and in exer-
cise duration fromþ0.3 min toþ3.1 min. There was a single RCT re-
port of peak oxygen uptake change, -0.1 mL/kg/min.
Discussion
This is the first meta-analysis assessing the role of right ventricular
pacing as a treatment for LVOTO in HOCM. We found that, in
blinded RCTs, pacing reduces LVOTg and shows a non-significant
trend to reduce NYHA class. Unblinded observational studies report
very much larger symptomatic effects, suggesting an unintentional
bias much larger than any genuine effect of the pacing.
Echocardiographic gradient assessments, which appear less vulner-
able to this bias, suggest a progressive enhancement of the therapeut-
ic effect with the passage of time.
Left ventricular outflow tract gradient
reduction
The meta-analysed RCT data strongly supports the concept that pac-
ing reduces measured LVOTg. There are broadly four mechanisms
by which pacing can have an influence. Right ventricular pacing causes
incoordination of ventricular activation which may reduce the driving
force of ventricular ejection. The altered ventricular activation se-
quence attenuates the tendency of the left ventricular outflow tract
(LVOT) lumen to become very small during systole. Atrioventricular
(AV) sequential pacing alters ventricular filling through a change in
AV delay, which impacts on ventricular ejection. Finally, knowledge
that the patient is receiving a treatment believed to decrease LVOTg
may cause an unintended bias of the echocardiographer to try less
hard to find a high gradient.
Randomization with allocation concealment (‘blinding’) is the most
effective approach to reduce unintended bias when evaluating thera-
pies. Under blinded conditions each of the trials individually showed
that pacing reduced gradient. The measured effect was much larger
in the (unblinded) observational studies, -55% rather than -35%
(P= 0.0351 for difference in study designs). While it is not certain
that the much larger effect sizes reported by unblinded studies is due
to unintended bias, it is difficult to imagine that the patient groups or
procedural characteristics were so markedly different between the
two study designs.
Symptoms without blinding
The blinded RCTs showed an encouraging trend towards a statistical-
ly significant reduction in NYHA class. A very much larger reduction
in NYHA class was reported by the unblinded observational studies.
The pooled estimates were so far apart their CIs did not overlap.
Indeed, the point estimates for eight out of nine observational studies
were for a greater NYHA reduction than even the highest upper limit
of the CI of any individual RCT.
We conclude from this that there may be a symptomatic benefit,
but that unblinded study design provides no useful information on it.
We cannot even use the unblinded symptomatic relief data to com-
pare different studies in order to select pacing approaches for future
blinded trials. This is because the great majority of the unblinded
symptomatic relief appears to be bias. Therefore, the differences be-
tween the unblinded symptom-relief effects reported by different
studies will be dominated by differences in the amount of bias rather
than clinically meaningful differences in protocol.
The origin of bias in unblinded observational studies investigating
subjective outcomes, such as NYHA, may be due to the anticipation
....................................................................................................................................................................................................................


















Kappenberger et al. Low risk Low risk Low risk Low risk Low risk Low risk Low risk
Nishimura et al. Uncertain Uncertain Low risk Low risk Low risk Low risk Low risk
Maron et al. Uncertain Uncertain Low risk Low risk Low risk Low risk Low risk
Mickelsen et al. Uncertain Uncertain High risk High risk Low risk Low risk High risk
328 A.D. Arnold et al.
Figure 2 Effect of right ventricular pacing on left ventricular outflow tract gradient at immediate (<12 h), short-term (12 h to 6 months), medium-
term (>6 months to <2 years), and long-term (at least 2 years) follow-up in non-randomized studies.
























..of effect by patients. However, the clinicians that rate patients’
NYHA status, who are also aware of treatment allocation, may also
contribute to bias with their own expectations of successful, or, in-
deed, unsuccessful, treatment.
Clinical implications
Knowing whether AV sequential right ventricular pacing is beneficial
in HOCM is important because many patients with HOCM require a
defibrillator and the modern era offers two changes from the trad-
itional dual-chamber, transvenous defibrillator. First, omitting the
atrial lead can reduce complication rates43 but it prevents AV se-
quential pacing. Second, subcutaneous defibrillators are now avail-
able, which are easier to remove than trans-venous defibrillators, but
do not have any pacing function.
If AV sequential right ventricular pacing genuinely helps patients,
then dual chamber, transvenous defibrillators would be preferable
over both single chamber transvenous and subcutaneous defibrilla-
tors. Although the blinded RCTs show only a non-significant trend to
reduction in NYHA class, the point estimate of the pooled effect size
is an OR of 1.82. Roughly speaking, this means patients are twice as
likely to feel better with pacing switched on rather than off. This is a
potentially meaningful clinical benefit and merits further investigation
through further blinded RCTs. Such RCTs need not be expensive or
resource-intensive, recruiting patients undergoing de novo implant-
ation. They could be conducted in patients who already have a defib-
rillator, with two randomized periods (pacing on vs. off) and
appropriately blinded evaluation. A 2012 Cochrane review2 of obser-
vational and randomized studies concluded, as we do, that the exist-
ing observational studies are of low quality due to inadequate
blinding but they did not quantify this effect as we have done. They
also call for high quality trials to investigate the potential for a true
symptomatic benefit.














P-value I2 heterogeneity P-value for
heterogeneity
Percentage change in LVOT gradient from baseline
9 234 Obs Immediate (<12 h) -40.8% -29.8 to -51.9 <0.0001 74.9% (high) <0.0001
10 243 Obs Short-term (12 h to 6 months) -54.3% -44.1 to -64.6 <0.0001 39.9% (moderate) 0.12
11 369 Obs Medium-term
(>6 months to <2 years)
-51.5% -44.5 to -58.4 <0.0001 10.8% (low) 0.3
16 644 Obs Long-term (at least 2 years) -66.8% -56.4 to -77.1 <0.0001 49.9% (moderate) 0.01
4 115 RCT Short-term (1–3 months) -35% -23.2 to 46.9 <0.0001 0% (low) 0.75
Odds ratio for improved NYHA class from baseline
9 388 Obs All follow-up durations 8.39 4.39 to 16.04 <0.0001 74.9% (high) <0.0001
3 137 RCT All follow-up durations 1.82 0.96 to 3.44 0.066 81.7% (high) 0.0042
Obs, observational studies (non-randomized); RCT, randomized controlled crossover trials.















..The clear evidence of gradient reduction by pacing should not be
assumed to prove that symptoms also improve. This is because pac-
ing (i) reduces the force of contraction by inducing incoordination,
(ii) reduces the impingement of the LVOT during systole, and (iii) ne-
cessarily alters filling since the paced activation must begin before the
native activation would have otherwise occurred. The symptomatic
effect will therefore be a result of not only changes in LVOT calibre
but also ventricular filling and ejection. The choice of AV delay may
be important. Applying a very short AV delay almost always reduces
stroke volume, even if systolic LVOT calibre is increased. It is unclear
how to programme the AV delay of a pacemaker in a patient with
HOCM, to provide a net advantage. Each of the studies has taken a
different approach, which may have contributed to the lack of transla-
tion of gradient reduction to symptomatic benefit, and more work
on this is required. The TRICHAMPION trial is underway, which is
examining the role of AV nodal ablation, for complete control of AV
delay, with biventricular pacing. Importantly, not all symptoms contri-
buting to NYHA status in HCM are due to LVOTO, some maybe
due to the cardiomyopathic process itself or comorbidities, and thus
unaffected by pacing.
Figure 4 Effect of right ventricular pacing on New York Heart Association class at short-term follow-up (1–3 months) in non-randomized studies.
Figure 5 Effect of right ventricular pacing on New York Heart Association class at short-term follow-up (1–3 months) in crossover randomized
controlled trials.
























































































The meta-regression of gradient with respect to follow-up dur-
ation suggests a progressive enlargement of the therapeutic effect
with longer follow-up across all published data, as has been noted be-
fore within single studies.34,40 It is not yet clear what the mechanism
for such a progression might be. One possibility is progressive
changes in the structure of the ventricle. However, it should be
remembered that long-term right ventricular pacing is known to
cause left ventricular function to deteriorate, and therefore, a long-
term reduction in gradient should not automatically be assumed to
be beneficial.
Limitations
There were only four RCTs, although all were blinded. Studies most-
ly did not report lead position or baseline QRS morphology, prevent-
ing separate analysis of the apical and septal positions or the
presence of pre-existing bundle branch block or meta-regression for
these variables. The apical lead position may be expected to result in
more dyssynchronous activation and thus greater ‘beneficial’ LVOTg
reduction, but this may be offset, or even superceded, by
dyssynchrony-related reduction in myocardial performance. This has
importance in procedure technique as achieving an apical lead pos-
ition in severe hypertrophy can be technically challenging.
Many studies reported the mean baseline (unpaced) and the mean
follow-up (paced) LVOTg and NYHA class with a categorical descrip-
tion of the P-value (e.g. ‘P< 0.05’) for the statistical test for differences
between them. The most useful value, however, would be the mean
intra-patient change in LVOTg along with its CI, standard error, stand-
ard deviation, or precise P-value. This has limited the precision with
which we can calculate the CI for the pooled estimate for the change
in LVOTg and NYHA, but has not affected the point-estimate.
Conclusions
The blinded RCTs show that AV sequential right ventricular pacing
reduces LVOTg in HOCM, and shows a trend to benefit in symptoms
that is not statistically significant but of a potentially clinically meaning-
ful size. This may have implications for the choice of defibrillator to
implant in HOCM. More research is needed into appropriate selec-
tion of AV delay. More blinded RCTs on symptom relief are required
and they need not be very demanding or expensive.
Unblinded observational studies report substantially larger gradi-
ent reductions and very much larger symptom reductions. The differ-
ence between the effect sizes reported by the two study designs
(RCT vs. observational) is so large that observational data are of un-
certain value in progressing the field. This is particularly so for symp-
toms, where the unblinded effect sizes appear to be scaled up by
450%.
Supplementary material
Supplementary material is available at European Heart Journal – Quality
of Care and Clinical Outcomes online.
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